Bladder Relaxing Medications for Overactive Bladder
First-Line Treatment: Behavioral Therapy
- The American Urological Association recommends that all patients with overactive bladder should receive behavioral therapies as first-line treatment before starting any bladder relaxing medications 1
- Behavioral treatments, such as bladder training, pelvic floor muscle exercises, and fluid management, are as effective as antimuscarinic medications for reducing symptoms and are risk-free 1
- These interventions significantly reduce incontinence episodes, frequency, nocturia, and improve quality of life 1
- Weight loss of just 8% in obese women reduced urgency incontinence episodes by 42% 1
- A 25% reduction in fluid intake and caffeine reduction both significantly decreased frequency and urgency 1
Second-Line Treatment: Oral Antimuscarinic Medications
- The American Urological Association recommends that oral antimuscarinic agents should be offered as second-line pharmacologic therapy when behavioral therapy alone is insufficient 1
- No compelling evidence exists for differential efficacy across antimuscarinic medications, such as darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, and trospium 1
- All antimuscarinic medications reduce symptoms but commonly cause non-life-threatening side effects, including dry mouth, constipation, dry eyes, blurred vision, dyspepsia, UTI, urinary retention, and impaired cognitive function 1
- Patients with more severe baseline symptoms experience greater absolute symptom reductions 1
Alternative Second-Line Treatment: β3-Adrenoceptor Agonist
- The European Association of Urology recommends mirabegron, a β3-adrenoceptor agonist, as an effective alternative second-line option, particularly for patients concerned about antimuscarinic side effects 2
- Mirabegron demonstrates fewer anticholinergic side effects, such as dry mouth, constipation, or cognitive impairment, compared to antimuscarinics 5
- Mirabegron has better adherence rates compared to antimuscarinics 2
- Mirabegron is effective in both men and women with overactive bladder 2
Combination Therapy for Refractory Symptoms
- The American Urological Association recommends combination therapy with mirabegron plus an antimuscarinic agent, particularly solifenacin, for patients with inadequate response to monotherapy 3
- Combination therapy demonstrates superior reduction in urinary incontinence episodes, micturitions, urgency episodes, and nocturia compared to either monotherapy 4
Critical Contraindications and Precautions
- The American Urological Association recommends that antimuscarinics are contraindicated in patients with narrow-angle glaucoma, unless approved by a treating ophthalmologist, and in patients using solid oral forms of potassium chloride 1
- Antimuscarinics should be used with extreme caution in patients with impaired gastric emptying, history of urinary retention, and men with bladder outlet obstruction 1
- Mirabegron should be administered with caution when combined with antimuscarinic medications due to increased risk of urinary retention, especially in patients with bladder outlet obstruction 3
Monitoring During Treatment
- The American Urological Association recommends monitoring for urinary retention, cognitive function, and anticholinergic side effects in patients receiving antimuscarinic therapy 1
- Regular blood pressure monitoring is recommended for patients receiving mirabegron therapy, especially initially and in hypertensive patients 3
- Discontinue mirabegron if worsening voiding symptoms or urinary stream occurs 3